©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Transcriptional Repression by the Human Homeobox Protein EVX1 in Transfected Mammalian Cells (*)

(Received for publication, August 10, 1995)

Paola Briata (1)(§) Rinke Van De Werken (1) Irma Airoldi (1)(¶) Cristina Ilengo (1) Erica Di Blas (1) Edoardo Boncinelli (2) Giorgio Corte (1) (3)

From the  (1)Laboratory of Immunobiology I.S.T., Advanced Biotechnology Center, 16132 Genova, Italy, (2)DIBIT H. S. Raffaele, 20132 Milano, Italy, and (3)Institute of Biochemistry, Genoa University Medical School, 16132 Genova, Italy

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The human homeobox protein EVX1 (EVX1) is thought to play an important role during embryogenesis. In this study, the effect of EVX1 on gene transcription has been investigated in transfected mammalian cells. EVX1 expression represses transcription of a reporter gene directed by either cell-specific or viral promoter/enhancer sequences in a variety of mammalian cell lines and in a concentration-dependent manner. Transcriptional repression is independent of the presence of DNA-binding sites for EVX1 in all the promoters we tested. Furthermore, repression by EVX1 is evident also using a TATA-less minimal promoter in the reporter construct. A carboxyl-terminal proline/alanine-rich region of EVX1 seems to be responsible for the transcriptional repression activity, as suggested by transfection of EVX1 mutants. We speculate that the repressor function of EVX1 contributes to its proposed role in embryogenesis.


INTRODUCTION

Homeobox genes code for transcription factors containing a trihelical DNA-binding motif, termed homeodomain (HD) (^1)((1, 2, 3) , and references cited therein). The HD is highly conserved with respect to structure and function throughout evolution and is a common component of numerous proteins that regulate transcription during development (for reviews, see (4, 5, 6) ). The functions of HD proteins range from activities in directing pattern formation to more restricted roles in regulating specific cell fate(3, 7) . The products of vertebrate homeobox-containing genes have been shown to bind DNA in vitro(8, 9) and to regulate gene transcription through specific target sequences in cell culture(10, 11) . It is unlikely that HD-containing proteins exert their different selective functions in vivo only through protein-DNA interactions, since they share similar DNA-binding specificities in vitro(4, 5) . Thus, it is presumed that although a single HD has the potential to bind to many DNA-target sites it may be specifically recruited into a functional complex at only a subset of those sites by selective protein-protein interactions(12, 13, 14, 15) . Furthermore, in some cases the HD has been demonstrated to be dispensable for activity in vivo(16, 17) .

Recently, the human homeobox genes EVX1 and EVX2 have been isolated and sequenced(18, 19) . These genes encode proteins containing a HD closely related to that encoded by the Drosophila even-skipped, which belongs to the pair-rule class of segmentation genes and is required for the proper development of the metameric body plan of the fruit fly(20, 21, 22) . Also the murine Evx 1 and Evx 2 genes have been cloned, and Evx 1 expression pattern during mouse embryogenesis has been studied(23) . During early embryogenesis, Evx 1 is expressed in a biphasic manner. From day 7 to 9 of development its expression emerges at the posterior end of the embryo within the primitive ectoderm and later in the mesoderm and neuroectoderm. From day 10 to 12.5, Evx 1 transcripts are restricted to specific cells within the neural tube and hindbrain, while no expression is detectable in a variety of adult tissues. Spyropoulos et al.(24) have recently shown that the targeted disruption of the Evx 1 gene in mice causes early postimplantation lethality of the conceptus.

Several authors have reported that the even-skipped gene product acts as a transcriptional repressor both in in vitro assays (25, 26, 27) and in cell transfection experiments(28, 29) . On the contrary, Jones et al.(30) showed that the mouse Evx 1 protein induces the expression of a reporter gene driven by the chicken Tenascin-C promoter. The same authors restricted the sequences that contributed to the activation to a segment containing a TRE known to bind transcription factors belonging to the AP-1 family. Currently, the role of the human EVX1 and EVX2 proteins in gene transcription is unknown.

The aim of our study was to investigate the transcriptional activity of EVX1 in transfected mammalian cells. Our data indicate that EVX1 expression strongly reduces, in a concentration-dependent manner, the basal and activated transcription of the reporter gene CAT directed by a variety of cell-specific and viral promoters in several different mammalian cell lines. EVX1 transcriptional repressor function is evident using both TATA-containing and TATA-less promoters. We also show that the repressor function of EVX1 is contained within a C-terminal region rich in alanine and proline residues and is independent of the presence of DNA-binding sites for EVX1.


EXPERIMENTAL PROCEDURES

Expression and Purification of EVX1 Recombinant Protein

EVX1 protein was produced in the baculovirus system according to the method previously described in detail (9) with minor modifications. Briefly, pVL941/EVX1 was obtained by inserting the filled in Sau3AI-Sau3AI (1453 bp) EVX1 cDNA fragment (18) in the filled in BamHI cloning site of pVL941 (Pharmingen, San Diego, CA). Recombinant baculovirus particles (Baculogold/EVX1) were obtained by transfecting Sf9 cells with the wild type Baculogold (Pharmingen) viral DNA together with pVL941/EVX1 and purified by limiting dilution and dot hybridization. For the production of EVX1 protein, 500 times 10^6 Sf9 cells were infected with five plaque-forming units/cell of the recombinant virus, and cells were recovered and lysed as described previously(9) . Both the cytoplasmic and the nuclear lysates were analyzed by SDS-polyacrylamide gel electrophoresis and stained with silver. A band that was absent in lysates from cells infected with a control virus was present in the profile of the nuclear lysates, accounting for approximately 2% of the total proteins (not shown). EVX1 protein was purified by ion exchange chromatography using Q and S Sepharose Fast Flow columns (Pharmacia Biotech, Inc.). After elution, the fractions containing the recombinant protein were renatured by extensive dialysis against buffer D (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM 1,4-dithiothreitol) at 4 °C. The recombinant protein was stored in buffer D supplemented with 20% glycerol at -80 °C.

General handling techniques for baculovirus expression system were performed essentially as described in (31) .

Cells, Antibodies, and Western Blotting

HeLa human cervix carcinoma cells, F9 teratocarcinoma cells, and InR1-G9 hamster glucagonoma cells (32) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. beta-TC1 mouse insulinoma cells (33) were cultured in Dulbecco's modified Eagle's medium supplemented with 12.5% horse serum, 2.5% fetal calf serum, glutamine, penicillin, and streptomycin as above. NIH-3T3, mouse fibroblast cells, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% bovine calf serum, glutamine, penicillin, and streptomycin as detailed above.

Mouse monoclonal antibodies to EVX1 were produced and characterized according to methods previously described(34, 35) . Determination of Ig classes was carried out by standard procedures utilizing the Mouse Typer Sub-Isotyping kit (Bio-Rad).

For immunoblot analysis, nuclear lysates of infected Sf9 cells were electrophoresed in 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes according to standard procedures. The filters were incubated with the supernatant of hybridoma cells, followed by an alkaline phosphatase-conjugated goat anti-mouse antibody from Sigma. Nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-1-phosphate were used as the substrates (Promega, Madison, WI) with a positive reaction resulting in purple color.

Immunofluorescence and Immunohistochemistry

For immunofluorescence, cytospins were prepared and fixed in acetone at -20 °C for 5 min. Cells were incubated for 2-16 h at room temperature with supernatant of hybridoma cells, followed by extensive washes and by incubation with rhodaminated goat anti-mouse IgG + IgM (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h at room temperature.

Immunohistochemistry was performed according to the streptavidin-biotin complex technique using a commercially available kit system (Dako, Glostrup, Denmark). Nuclei were counterstained for 5 min with Mayer's hematoxylin solution (Sigma).

Plasmids

p[-1.1]GLU-CAT and p[-0.35]GLU-CAT were previously described and characterized (36, 37, 38) and were a gift from Drs. R. Gherzi and B. Göke (Marburg, Germany), pCAT-Promoter was purchased from Promega, pRSV-CAT (39) was obtained from Dr. M. Beato (Marburg, Germany), and p7B2-I-CAT was described previously (40) and obtained from Dr. B. Göke (Marburg, Germany). pInr-CAT was constructed by cloning synthetic oligonucleotides containing the appropriate sequence (41) into the PstI and XbaI sites of pCAT-Basic vector purchased from Promega. The pCMV-EVX1 expression construct was generated by cloning the Klenow-filled in Sau3AI-Sau3AI fragment containing the complete open reading frame of the EVX1 cDNA (18) into the Klenow-filled in HindIII site of the pRC-CMV expression vector purchased from Invitrogen Corp. (San Diego, CA). The pCMV-HOXD4 expression construct was generated by cloning the ApaI-ApaI fragment containing the complete open reading frame of the HOXD4 cDNA (42) into the ApaI site of the pRC-CMV expression vector. pCMV-DeltaEVX1 and pCMV-EVX1 expression constructs were generated by cloning PCR-amplified fragments containing the 5` 750 bp and the 3` 675 bp of the open reading frame of EVX1 cDNA, respectively, in the pRC-CMV expression vector. The chimeric construct pCMV-HOXC6/EVX1 was created by ligating the 5` 612-bp fragment of HOXC6 (indicated as pCMV-HOXC6N when cloned into pRC-CMV and utilized as the control for transfection experiments; (9) and references cited therein) with the 3` 459-bp fragment of EVX1 and cloning the construct into the pRC-CMV vector. For PCR reactions, ULTma DNA polymerase from Perkin-Elmer was used. Oligonucleotides were obtained from TIB MolBiol, Genova, Italy.

General handling of plasmid DNA was performed according to previously described techniques(43) .

DNA Transfections and CAT Assays

InR1-G9 and beta-TC1 cells transient transfection was performed essentially as described by Fehmann and Habener (44) with the modification reported in (38) . HeLa and F9 cells were transiently transfected by the calcium phosphate technique, performed exactly as reported in (45) . Transient transfection of NIH-3T3 by the electroporation technique was performed using a Gene Pulser apparatus (Bio-Rad) as follows: 4 times 10^6 NIH-3T3 cells in complete medium were electroporated by applying a voltage of 0.25 kV and a capacitance of 960 microfarads. In each transfection experiment the cell number of each well was controlled by both protein concentration assays and cell counting, and variation never exceeded 10%. pRSV-CAT was used in each transfection as an internal control of transfection efficiency. Cell treatment with signal-transducing agents started 30 h after transfection and was carried out for 16 h in medium without serum. Thereafter, cells were harvested, extracts were prepared, and CAT activity was measured as detailed by Sambrook et al.(43) , according to the modifications described in (46) . Experiments were performed in duplicate and repeated a minimum of three times.

RNase Protection and RT-PCR Analysis

Total RNA was prepared from InR1-G9 cells transfected with p[-1.1]GLU-CAT and either pRC-CMV or pCMV-EVX1 by the guanidine/cesium chloride method(45) . RNase protection analysis was performed using the RPA II kit (Ambion, Austin, TX) following the manufacturer's instructions. As a probe, an antisense strand RNA provided by Ambion (CAT-Direct) was used. RT-PCR was performed exactly as reported in (47) .


RESULTS

Expression of the EVX1 Protein and Production of Monoclonal Antibodies

EVX1 was expressed in the baculovirus system and purified to near homogeneity (Fig. 1A), as described under ``Experimental Procedures.'' When analyzed by SDS-polyacrylamide gel electrophoresis, the recombinant protein showed an apparent molecular mass higher (62 kDa) than predicted by its amino acid sequence (42.5 kDa). Mouse monoclonal antibodies were prepared against EVX1 as described under ``Experimental Procedures.'' The antibody used in this study (mAb B6-41) is an IgG1 that strongly reacts in Western blot with EVX1 in total nuclear lysates of Sf9 cells infected with the recombinant virus Baculogold/EVX1. No immunoreactivity to HOXB7, HOXC6, HOXD4, and HOXA10 in the nuclear lysates of Sf9 cells infected with the corresponding recombinant viruses was detected (Fig. 1A and data not shown). Furthermore, nuclei of Sf9 cells infected with the Baculogold/EVX1 recombinant virus showed a bright staining in immunofluorescence when reacted with mAb B6-41, while nuclei of Sf9 cells either noninfected or infected with Baculogold/HOXB7, HOXC6, HOXD4, or HOXA10, were negative (data not shown).


Figure 1: EVX1 is expressed in nuclei of transfected cells and is recognized by a monoclonal antibody raised against the recombinant protein. A, left, SDS-polyacrylamide gel electrophoresis analysis of the purified recombinant EVX1. 100 ng of the recombinant protein, purified as detailed under ``Experimental Procedures,'' were loaded on a 10% reducing acrylamide gel and, after electrophoresis, the gel was silver-stained. Molecular mass markers are indicated on the left side. Right, immunoreactivity of mAb B6-41 in Western blot on nuclear lysates of Sf9 cells expressing HOXD4 and EVX1 proteins. Molecular mass markers are indicated on the right side. B, immunohistochemical analysis of HeLa cells transiently transfected with pRC-CMV vector (negative control) utilizing mAb B6-41. Magnification is times 500. C, immunohistochemical analysis of HeLa cells transiently transfected with pCMV-EVX1 vector utilizing mAb B6-41. Magnification is times 500. D, immunofluorescence analysis of InR1-G9 cells transiently transfected with pCMV-EVX1. Magnification is times 500.



In order to determine whether mAb B6-41 is able to recognize the fully processed EVX1 expressed in human cells, HeLa cells were transiently transfected with the expression construct pCMV-EVX1 (see ``Experimental Procedures''). Both in immunofluorescence and immunohistochemistry assays nuclei of approximately 20% of HeLa cells showed a strong staining when reacted with mAb B6-41, while cells transiently transfected with pRC-CMV were negative (Fig. 1, B and C).

EVX1 Represses Basal and Activated Transcription from Several Promoters

To investigate the transcriptional properties of the human EVX1 in vivo we transiently cotransfected glucagonoma cells InR1-G9 with an EVX1 expression vector (pCMV-EVX1) together with two plasmids (p[-1.1]GLU-CAT and p[-0.35]GLU-CAT) in which the transcription of the reporter CAT is directed by regions of the rat proglucagon gene promoter(36, 37, 38) . p[-1.1]GLU-CAT contains 1.1 kilobases of the promoter sequence(38) , which includes, between positions -503 and -487, (^2)the element ANATTANNNNNTAATNG (which is very similar to the consensus TNATTANNNNNTAATNG found to be bound with high affinity by the human recombinant EVX1). (^3)On the contrary, p[-0.35]GLU-CAT does not contain this consensus sequence. Homeobox proteins have been reported to play important roles in cell-specific gene transcription in pancreatic islet cells(48, 49, 50) . Thus, it was not surprising to find a putative EVX1 DNA-binding site in the proglucagon gene promoter. As previously reported, p[-1.1]GLU-CAT and p[-0.35]GLU-CAT direct high levels of CAT transcription in InR1-G9 cells, p[-0.35]GLU-CAT being less effective than p[-1.1]GLU-CAT(38) . As shown in Fig. 2A and in Fig. 4, the basal transcriptional activity of either p[-1.1]GLU-CAT or p[-0.35]GLU-CAT was approximately 90% reduced when each of the reporter plasmids was cotransfected with the expression plasmid pCMV-EVX1 in InR1-G9 cells in comparison with either the pRC-CMV alone or the expression plasmid containing the HOXD4 cDNA (pCMV-HOXD4; see ``Experimental Procedures''). These observations, together with results presented below (see Fig. 6), suggest that EVX1 represses transcription directed by a promoter either containing or not containing its high affinity DNA target sites.


Figure 2: EVX1 represses basal and activated transcriptional activity of the rat proglucagon gene promoter in transiently transfected InR1-G9 cells. A, cells were transiently transfected in suspension using the DEAE-dextran technique (see ``Experimental Procedures'') with 10 µg of the reporter plasmid p[-1.1]GLU-CAT and 10 µg of the effector plasmids indicated. 30 h later cells were changed to serum-free medium with or without 20 µM forskolin. After a further 16 h, cells were harvested, and the CAT activity present in aliquots of cell extracts was measured, as detailed under ``Experimental Procedures.'' The results are the average (± S.E.) of five independent experiments (performed in duplicate). In the lower part of the panel, a representative autoradiogram of one experiment (performed in duplicate) is shown. B, cells were transfected with 10 µg of the reporter plasmid p[-1.1]GLU-CAT and 10 µg of the effector plasmids indicated. 30 h later cells were changed to serum-free medium with or without 160 nM phorbol 12-myristate 13-acetate. After a further 16 h, cells were harvested, and the CAT activity present in aliquots of cell extracts was measured, as detailed under ``Experimental Procedures.'' In the lower part of the panel, a representative autoradiogram of one experiment (performed in duplicate) is shown.




Figure 4: EVX1 represses the transcriptional activity of several cell-specific and viral promoter/enhancer sequences in several different transiently transfected cells. Indicated cells were transiently transfected (detailed under ``Experimental Procedures'') with 10 µg of the reporter plasmids indicated and 10 µg of the pCMV-EVX1 expression plasmid. 46 h later, cells were harvested, and the CAT activity present in aliquots of cell extracts was measured as detailed under ``Experimental Procedures.'' Results represent the average (± S.E.) of three independent experiments performed in duplicate.




Figure 6: EVX1 represses the transcriptional activity of a minimal TATA-less promoter in transiently transfected InR1-G9 and NIH-3T3 cells. Cells were transiently transfected in suspension using the DEAE-dextran technique with 10 µg of the reporter construct and 10 µg of effector plasmids, as indicated. 46 h after the transfection, cells were harvested, and the CAT activity present in aliquots of cell lysates was assayed, as detailed under ``Experimental Procedures.'' Results represent the average (± S.E.) of three independent experiments (performed in duplicate). In the lower part of the figure, a representative autoradiogram of one experiment (performed in duplicate) for each cell line is shown.



Next we investigated whether transcriptional repression is exerted by EVX1 at any concentration of the transfected expression vector. As shown in Fig. 3, repression by EVX1 is a concentration-dependent phenomenon in a range of transfected pCMV-EVX1 vector from 0.1 to 8 µg.


Figure 3: EVX1 functions as a transcriptional repressor in a concentration-dependent manner. Subconfluent InR1-G9 cells were transfected in suspension using the DEAE-dextran technique with 10 µg of the reporter plasmid p[-1.1]GLU-CAT and different amounts (as indicated) of pCMV-EVX1. 46 h after transfection, cells were harvested, and aliquots of lysates were assayed for CAT activity as detailed under ``Experimental Procedures.'' The results are the average (± S.E.) of three independent experiments performed in duplicate.



It has been reported that the mouse Evx 1 activates the chicken Tenascin-C promoter in transfected cells by interacting with a TRE(30) . The rat proglucagon gene promoter contains binding sites for transcription factors belonging to the AP1 and CREB families and is regulated by protein kinase A and protein kinase C activators in pancreatic cell lines(36, 37, 38) . The transcriptional activation of p[-1.1]GLU-CAT by forskolin (Fig. 2A) and phorbol 12-myristate 13-acetate (Fig. 2B) was approximately 9O% reduced by cotransfection of pCMV-EVX1 in comparison with pRC-CMV alone. Similar results were obtained using beta-TC1 insulinoma cells (not shown).

To investigate whether the transcriptional repression is restricted to the specific promoter we used in the above described experiments, other reporter plasmids containing mammalian and viral promoter/enhancer regions were tested in different mammalian cell lines. The cotransfection of pCMV-EVX1 with pRSV-CAT, pCAT-promoter, and p7B2-I-CAT, containing 524 bp of the 3` LTR of the Rous sarcoma virus (39) , 202 bp of the SV40 promoter(51) , and 1.5 kilobases of the 5`-flanking region plus 1.5 kilobases of the first intron of the human 7B2 gene (which encodes a neuroendocrine molecular chaperone expressed in insulinoma and glucagonoma cells)(52) , respectively, decreased the transcriptional activity of the reporter by 50-90% in different cell lines (Fig. 4, and data not shown). These results indicate that the transfected EVX1 exerts its transcriptional repressor activity in cells either expressing or not expressing the endogenous EVXI and that this effect is not promoter-specific.

The observed repression of CAT activity by EVX1 corresponds to a decrease in CAT mRNA, as measured either by RNase protection analysis or by RT-PCR experiments (Fig. 5). It is noteworthy that the CAT transcript is strongly reduced in EVX1-transfected cells 24 h after transfection and that the reduction persists after 46 h (Fig. 5A). This finding suggests that the observed EVX1 effect on CAT activity predominantly depends on the transcription rate of CAT mRNA. This finding is supported by the RT-PCR experiments depicted in Fig. 5B.


Figure 5: RNase protection and RT-PCR analysis of the CAT transcript in transfected InR1-G9 cells. A, subconfluent cultures of InR1-G9 cells were transiently transfected using the calcium phosphate technique with p[-1.1]GLU-CAT together with either pRC-CMV or pCMV-EVX1. Total RNA was prepared at different times, and 10 µg RNA were subjected to RNase protection analysis as indicated under ``Experimental Procedures.'' Lane 1, RNA CAT probe; lane 2, negative control (Escherichia coli RNA CAT); lane 3, positive control (E. coli RNA CAT); lanes 4 and 6, RNA from pRC-CMV transfected cells, 24 and 46 h after transfection, respectively; lanes 5 and 7, RNA from pCMV-EVX1-transfected cells, 24 and 46 h after transfection, respectively. Arrows point the RNA probe and the protected CAT fragment, respectively. Expression of beta-actin is shown in the lower part of the panel as an internal control. The numbers to the left indicate the length of the fragments in nucleotides. B, cell transfection and RNA isolation were performed as in panel A. 5 ng of RNA were subjected to RT-PCR as described under ``Experimental Procedures.'' RT-PCR products were electrophoresed, and agarose gels were stained with ethidium bromide and photographed. The bands corresponding to the CAT transcript were densitometrically scanned, and the relative absorbances (expressed in arbitrary units) of two independent experiments were 23.1 (lane 1, pRC-CMV transfected cells) and 2.5 (lane 2, pCMV-EVX1 transfected cells).



In each transfection experiment, both the expression and the correct transport to the nucleus of the EVX1 protein were checked by immunofluorescence using mAb B6-41 (Fig. 1D, and data not shown).

EVX1 Represses Transcription from a TATA-less Minimal Promoter

Although the results presented above suggest that the effect of EVX1 does not require its binding to a specific DNA motif, we investigated whether EVX1 represses gene transcription from a reporter plasmid containing only a single promoter element, the 17-bp mammalian terminal deoxynucleotidyl transferase initiator element (pInr-CAT) (41) belonging to a class of promoters that have no apparent TATA element. We used a minimal TATA-less promoter to eliminate any possible interference from sequences that could mimic the core sequence ATTA known to interact with homeobox proteins. As shown in Fig. 6, in InR1-G9 cells, the weak transcriptional activity of pInr-CAT was 90% inhibited by the cotransfection of pCMV-EVX1. In order to increase the transfection efficiency, we transfected NIH-3T3 cells by electroporation and obtained similar results. Cells cotransfected with pCMV-EVX1 showed a transcriptional activity of pInr-CAT approximately 75% lower than cells cotransfected either with pRC-CMV alone or with pCMV-HOXD4 (Fig. 6).

The Deletion Mutant DeltaEVX1, Which Lacks the C Terminus Loses the Ability to Inhibit Transcription

No clear amino acid sequence similarities between the repressing domains of different transcriptional repressors have been described. These domains are, however, usually rich in alanine, glutamine, and/or proline residues (29, 53, 54) . The EVX1 protein does contain such a region rich in alanine and proline residues carboxyl-terminal to the HD. Thus, we constructed an expression vector (pCMV-DeltaEVX1) cloning a deletion mutant lacking the 3` 157 nucleotides of the EVX1 coding sequence in the pRC-CMV (Fig. 7A and ``Experimental Procedures''). Immunohistochemistry and immunofluorescence assays on InR1-G9 and HeLa cells transiently transfected with pCMV-DeltaEVX1 clearly showed a nuclear staining with mAb B6-41, implying that (i) our molecular manipulations did not remove the epitope against which the antibody is directed and that (ii) the deleted molecule is correctly processed and transported to the nucleus (Fig. 7B, and data not shown). Furthermore, the recombinant EVX1 expressed using the baculovirus system and purified to near homogeneity is able to bind the EVX1-specific DNA-binding sites with the same affinity as the wild type EVX1 (data not shown). Transfection of pCMV-DeltaEVX1 in InR1-G9 cells did not affect [-1.1]GLU-CAT transcription (Fig. 7C). Similar results were obtained in HeLa cells using pInr-CAT as a reporter (data not shown). As a control, we constructed a 3` deletion mutant of EVX1 (pCMV-EVX1; see ``Experimental Procedures'' and Fig. 7A). As reported in Fig. 7C, cotransfection of pCMV-EVX1 in InR1-G9 cells led to a reduction of CAT activity comparable with that produced by wild type pCMV-EVX1. The hypothesis that the C-terminal region of EVX1 is responsible for the transcriptional inhibitory activity of the protein is strengthened by the observation that a transfected chimeric expression construct, in which the HOXC6 cDNA lacking the 3` 93-bp fragment of the open reading frame was fused with the above mentioned EVX1 region (pCMV-HOXC6/EVX1; see ``Experimental Procedures'' and Fig. 7A), 70% inhibited the CAT activity of the reporter plasmid in comparison with the control (pCMV-HOXC6N, Fig. 7C).


Figure 7: The deletion mutant DeltaEVX1 lacking the C terminus loses the ability to repress transcription in transfected cells. A, a schematic representation of EVX1, the deletion mutants, HOXC6, and the chimeric construct HOXC6/EVX1. Details on the construction of the mutant expression vectors are reported under ``Experimental Procedures.'' B, immunohistochemical analysis of transiently transfected InR1-G9 cells with pCMV-DeltaEVX1 utilizing mAb B6-41. Magnification is times 250. C, InR1-G9 was transiently transfected with 10 µg of the reporter plasmid p[-1.1]GLU-CAT and 10 µg of the effector plasmids indicated. 46 h after transfection, cells were harvested, and the CAT activity present in aliquots of cell lysates was assayed as detailed under ``Experimental Procedures.'' Bars represent the average (± S.E.) of three independent experiments performed in duplicate.




DISCUSSION

Our findings indicate that a human HD protein, EVX1, is a potent transcriptional repressor and that this effect is independent of the presence of its specific DNA-binding sites in the promoter. Here we show that EVX1 represses basal and activated transcription directed by TATA-containing and TATA-less promoters. Furthermore, the carboxyl-terminal region of the protein seems to contain the ``repressor domain(s).''

It has been shown in Drosophila that Eve binds DNA (55) and functions as a sequence-specific transcriptional repressor in transfected cells (28, 29) and in transcriptionally competent extracts (25) . However, Han and Manley(29) , using Eve deletion mutants, observed a significant correlation between strong repression and weak binding to DNA. Moreover, TenHarmsel et al.(27) , in addition to a repressor mechanism based on Eve binding to its DNA sites, described also a second mechanism that does not require binding to DNA. These authors suggested that Eve might interact with the general transcription factors to inhibit their function. Thus, the finding that EVX1, which is homologous to Eve, represses reporter gene transcription directed by promoters lacking any obvious binding site for the protein is not totally unexpected. Furthermore, other HD proteins seem to behave similarly. Msx-1, a murine HD protein, inhibits transcription with a mechanism very similar to that we describe for EVX1(54) . Also SCIP, a member of the POU class of HD proteins, actively represses transcription of myelin-specific genes independently of the presence of its specific DNA binding sites on the promoter(56) . Much evidence indicates that the function of HD proteins in transcriptional regulation may not be limited to their interaction with specific DNA-binding sites. Although HD proteins share similar DNA-binding properties in vitro, they present different functional specificities in vivo, and this is likely due to protein-protein interactions(4, 5, 14, 57, 58) . Furthermore, several authors have shown that proteins lacking all or part of their HD may retain some aspects of function(16, 17, 54, 59) . Therefore, all of this experimental evidence indicates that the simple interaction between the HD and its DNA-binding site can be dispensable for some transcriptional properties of homeobox-containing proteins.

A comparative analysis of the amino acid sequences of EVX1 and Eve revealed that, apart from the highly conserved HD, the two proteins show an alanine-/proline-rich region present at the C-terminal end of both proteins in a position very close to the HD (data not shown). Although glutamine/alanine/proline richness is not a universal feature of active repressors, these domains have been found not only in Eve, but also in other well characterized transcriptional repressors such as engrailed, Krüppel, Wilms tumor gene product, and Msx-1(53, 54) . Furthermore, the Dr1 protein, which also contains a glutamine/alanine-rich region, has been shown to interact with TFIID and to inhibit transcription(60) . Indeed, we have shown that EVX1 protein, while still able to bind DNA with high affinity, loses its ability to repress transcription when the alanine- and proline-rich carboxyl-terminal portion of the protein is removed. Furthermore, this region confers transcriptional inhibitory potential to the HD protein HOXC6 which is per se unable to affect transcription of the reporter plasmids used.

In recent years there has been an explosion of information regarding the role of sequence-specific DNA binding proteins in the selective activation of eukaryotic promoters. On the contrary, less is known about how DNA binding proteins repress transcription (for reviews, see (53) and (61) -63). However, it is reasonable to believe that selective repression is an important mechanism of transcriptional control and that it could be widely used during development. Our results seem to rule out most of the repression mechanisms proposed for the eukaryotic gene transcriptional regulation(53, 61, 62, 63) . First, EVX1 does not compete with an activator protein for binding to the same DNA sequence, as it can inhibit promoters lacking its binding site. Second, a mechanism by which EVX1 would interact with a specific activator protein, preventing its contact with the transcription machinery, is made unlikely by the generality of the phenomenon we observed. A mechanism that must be taken into account when repression is observed, particularly in transient transfection assays, is termed ``squelching''(64) . In this case, transcriptional repression paradoxically results from the overexpression of an activating protein. Such repression requires neither specific DNA binding sites nor an intact DNA binding domain in the overexpressed protein and appears to result from the sequestration of other transcription factors with which the activator naturally interacts. Our data are not consistent with this explanation since (i) transcriptional activation was never observed under any circumstances we used, regardless of the promoter, the cell type or the concentration of the transfected EVX1 expression vector; (ii) the amount of the expression plasmid required for repression is within the range that is normally used to measure transcriptional activity in transient transfection assays(54) ; and (iii) preliminary results obtained in pools of HeLa cells stably transfected with pCMV-EVX1, which express relatively low levels of the protein in comparison to the transient transfectants, indicate that EVX1 represses transcription of transiently transfected reporter constructs. (^4)On the basis of our data, we can speculate that EVX1 functionally interferes with a general transcription factor. However, this interference cannot be due to a displacement of the factor caused by the binding of EVX1 to the TATA sequence, which could in principle mimic homeobox protein binding sites, because of its action on TATA-less promoters. The results seem then to indicate a mechanism by which EVX1, as other repressor proteins (60, 65, 66, 67) , interferes with a general transcription factor at an early stage of the assembly of the transcription initiation complex, thereby preventing its further assembly.

The potential for EVX1 to repress transcription through protein-protein rather than protein-DNA interactions may be an important feature of its proposed role as a regulator of embryogenesis.


FOOTNOTES

*
This work was partially supported by grants from AIRC, MURST, and Ministero della Sanità (to G. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed:Laboratory of Immunobiology, Advanced Biotechnology Center, Viale R. Benzi, 10, 16132 Genova, Italy. Tel.: 39-10-5737401; Fax: 39-10-5737405.

Recipient of an AIRC fellowship.

(^1)
The abbreviations used are: HD, homeodomain; TRE, 12-O-tetradecanoylphorbol 13-acetate response element; EVX1, human homeobox protein EVX1; CAT, chloramphenicol acetyltransferase; DEAE-dextran, diethylaminoethyl-dextran; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR; Eve, even-skipped product; mAb, monoclonal antibody; bp, base pair(s).

(^2)
EMBL accession number to the sequence: Z35161[GenBank].

(^3)
Antonio Daga and G. Corte, submitted for publication.

(^4)
P. Briata and G. Corte, unpublished results.


ACKNOWLEDGEMENTS

We are grateful to Dr. R. Gherzi (Genova), whose contribution to this paper has been crucial in terms of helpful discussion, critical advice, and technical support. We thank also Drs. B. Göke and M. Beato (Marburg), for providing plasmids and cells, Drs. R. Biassoni, B. Dozin, S. Ferrini, and L. Zardi (Genova) for sharing reagents, and Mrs. Margherita Isola for photographic work.


REFERENCES

  1. Levine, M., and Hoey, T. (1988) Cell 55, 537-540 [Medline] [Order article via Infotrieve]
  2. Hayashi, S., and Scott, M. P. (1990) Cell 63, 883-894 [Medline] [Order article via Infotrieve]
  3. McGinnis, W., and Krumlauf, R. (1992) Cell 68, 283-302 [Medline] [Order article via Infotrieve]
  4. Scott, M. P., Tammkun, J. W., and Hartzell, G. W. (1989) Biochim. Biophys. Acta 989, 25-48 [CrossRef][Medline] [Order article via Infotrieve]
  5. Laughon, A. (1991) Biochemistry 30, 11357-11367 [Medline] [Order article via Infotrieve]
  6. Gehring, W. J. (1993) Gene (Amst.) 135, 215-221 [CrossRef][Medline] [Order article via Infotrieve]
  7. Rosenfeld, M. G. (1991) Genes & Dev. 5, 897-907
  8. Odenwald, W. F., Garbern, J., Arnheiter, H., Tournier-Lasserve, E., and Lazzarini, R. A. (1989) Genes & Dev. 3, 158-172
  9. Corsetti, M. T., Briata, P., Sanseverino, L., Daga, A., Airoldi, I., Simeone, A., Palmisano, G., Angelini, C., Boncinelli, E., and Corte, G. (1992) Nucleic Acids Res. 20, 4465-4472 [Abstract]
  10. Zappavigna, V., Renucci, A., Izpisua-Belmonte, J. C., Urier, G., Peschle, C., and Duboule, D. (1991) EMBO J. 10, 4177-4187 [Abstract]
  11. Jones, F. S., Prediger, E. A., Bittner, D. A., De Robertis, E. M., and Edelman, G. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2086-2090 [Abstract]
  12. Stern, S., Tanaka, M., and Herr, W. Nature 345, 783-785
  13. Pomerantz, J. L., Kristie, T. M., and Sharp, P. A. (1992) Genes & Dev. 6, 2047-2057
  14. Zappavigna, V., Sartori, D., and Mavilio, F. (1994) Genes & Dev. 8, 732-744
  15. Johnson, F. B., Parker, E., and Krasnow, M. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 739-743 [Abstract]
  16. Ananthan, J., Baler, R., Morrissey, D., Zuo, J., Lan, Y., Weir, M., and Voellmy, R. (1993) Mol. Cell. Biol. 13, 1599-1609 [Abstract]
  17. Fitzpatrick, V. D., Percival-Smith, A., Ingles, C. J., and Krause, H. M. (1992) Nature 356, 610-612 [CrossRef][Medline] [Order article via Infotrieve]
  18. Faiella, A., D'Esposito, M., Rambaldi, M., Acampora, D., Balsofiore, S., Stornaiuolo, A., Mallamaci, A., Migliaccio, E., Gulisano, M., Simeone, A., and Boncinelli, E. (1992) Nucleic Acids Res. 23, 6541-6545
  19. D'Esposito, M., Morelli, F., Acampora, D., Migliaccio, E., Simeone, A., and Boncinelli, E. (1991) Genomics 10, 43-50 [Medline] [Order article via Infotrieve]
  20. Macdonald, P. M., Ingham, P., and Struhl, G. (1986) Cell 47, 721-734 [Medline] [Order article via Infotrieve]
  21. Frasch, M., Hoey, T., Rushlow, C., Doyle, H, and Levine, M. (1987) EMBO J. 6, 749-759 [Abstract]
  22. Jäckle, H., and Sauer, F. (1993) Curr. Opin. Cell Biol. 5, 505-512 [Medline] [Order article via Infotrieve]
  23. Bastian, H., and Gruss, P. (1990) EMBO J. 9, 1839-1852 [Abstract]
  24. Spyropoulos, D. D, and Capecchi, M. R. (1994) Genes & Dev. 8, 1949-1961
  25. Biggin, M. D., and Tjian, R. (1989) Cell 58, 433-440 [Medline] [Order article via Infotrieve]
  26. Johnson, F. B., and Krasnow, M. A. (1992) Genes & Dev. 6, 2177-2189
  27. TenHarmsel, A., Austin, R. J., Savenelli, N., and Biggin, M. D. (1993) Mol. Cell. Biol. 13, 2742-2752 [Abstract]
  28. Han, K., Levine, M. S., and Manley, J. (1989) Cell 56, 573-583 [Medline] [Order article via Infotrieve]
  29. Han, K., and Manley, J. L. (1993) Genes & Dev. 7, 491-503
  30. Jones, F. S., Chalepakis, G., Gruss, P., and Edelman, G. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2091-2095 [Abstract]
  31. Summers, M. D., and Smith, G. E. (1987) A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures , Texas Agricultural Experiment Station, Bulletin No. 1555
  32. Takaki, R., Ono, J., Nakamura, M., Yokogawa, Y., Kumae, S., Hiroaka, T., Yamaguchi, K., and Uchida, S. (1986) In Vitro Cell. & Dev. Biol. 22, 120-126
  33. Efrat, S., Linde, S., Kofod, M., Spector, D., Delamoy, M., Grant, S., Hanahan, D., and Baekkeskov, S. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9037-9041 [Abstract]
  34. Corte, G., Moretta, L., Damiani, G., Mingari, M. C., and Bargellesi, A. (1981) Eur. J. Immunol. 11, 162-170 [Medline] [Order article via Infotrieve]
  35. Gefter, M. L., Margulies, D. H., and Scharff, M. D. (1977) Somatic Cell Genet. 3, 231-237 [Medline] [Order article via Infotrieve]
  36. Drucker, D. J., Philippe, J., Jepeal, L., and Habener, J. F. (1987) J. Biol. Chem. 262, 15659-15665 [Abstract/Free Full Text]
  37. Knepel, W., Chafitz, J., and Habener, J. F. (1990) Mol. Cell. Biol. 10, 6799-6804 [Medline] [Order article via Infotrieve]
  38. Gherzi, R., Fehmann, H.-C., Volz, A., Ponassi, M., and Göke B. (1995) Exp. Cell Res. 218, 460-468 [CrossRef][Medline] [Order article via Infotrieve]
  39. Gorman, C. M., Merlino, G. T., Willingham, M. C., Pastan, I., and Howard, B. H. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 6777-6781 [Abstract]
  40. Waldbieser, G. C., Aimi, J., and Dixon, J. (1991) Endocrinology 128, 3228-3236 [Abstract]
  41. Smale, S. T., and Baltimore, D. (1989) Cell 57, 103-113 [Medline] [Order article via Infotrieve]
  42. Mavilio, F., Simeone, A., Giampaolo, A., Faiella, A., Zappavigna, V., Acampora, D., Poiana, G., Russo, G., Peschle, C., and Boncinelli, E., (1986) Nature 324, 664-668 [Medline] [Order article via Infotrieve]
  43. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  44. Fehmann, H.-C., and Habener, J. F. (1982) Endocrinology 130, 159-166 [Abstract]
  45. Ausubel, F. A., Brent, R., Kingstone, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1990) Current Protocols in Molecular Biology , Greene Publishing and Wiley-Interscience, New York, NY
  46. Pothier, F., Ouellet, M., Julien, J-P., and Guerin, S. L. (1992) DNA Cell Biol. 11, 83-90 [Medline] [Order article via Infotrieve]
  47. Gherzi, R., Ponassi, M., Gaggero, B., and Zardi, L. (1995) FEBS Lett. 369, 335-339 [CrossRef][Medline] [Order article via Infotrieve]
  48. Karlsson, O., Thor, S., Norberg, T., Ohlsson, H., and Edlund, T. (1990) Nature 344, 879-882 [CrossRef][Medline] [Order article via Infotrieve]
  49. Miller, C. P., McGehee, E., Jr., and Habener, J. F. (1994) EMBO J. 13, 1145-1156 [Abstract]
  50. Leonard, J., Peers, B., Johnson, T., Ferreri, K., Lee, S., and Montminy, M. R. (1993) Mol. Endocrinol. 7, 1275-1283 [Abstract]
  51. Rosenthal, N. (1987) in Methods in Enzymology , Vol. 152 (Berger, S. L., and Kimmel, A. R., eds) pp. 704-720, Academic Press, Inc., San Diego [Medline] [Order article via Infotrieve]
  52. Gherzi, R., Fehmann, H.-C., Eissele, R., and Göke, B. (1994) Exp. Cell Res. 213, 20-27 [CrossRef][Medline] [Order article via Infotrieve]
  53. Cowell, I. G. (1994) Trends Biochem. Sci. 19, 38-42 [CrossRef][Medline] [Order article via Infotrieve]
  54. Catron, K. M., Khang, H., Marshall, S. C., Inostroza, J. A., Wilson, J. M., and Abate, C. (1995) Mol. Cell. Biol. 15, 861-871 [Abstract]
  55. Hoey, T., and Levine, M. (1988) Nature 332, 858-861 [CrossRef][Medline] [Order article via Infotrieve]
  56. Monuki, E. S., Kuhn, R., and Lemke, G., (1993) Mech. Dev. 42, 15-32 [CrossRef][Medline] [Order article via Infotrieve]
  57. Kuziora, M. A., and McGinnis, W. (1989) Cell 59, 563-571 [Medline] [Order article via Infotrieve]
  58. Xue, D., Tu, Y., and Chalfie, M. (1993) Science 261, 1324-1326 [Medline] [Order article via Infotrieve]
  59. Vershon, A. K., Jin, Y., and Johnson, A. D. (1995) Genes & Dev. 9, 182-192
  60. Inostroza, J. A., Mermelstein, F. H., Ha, I., Lane, W. S., and Reinberg, D. (1992) Cell 70, 477-489 [Medline] [Order article via Infotrieve]
  61. Levine, M., and Manley, J. L. (1989) Cell 59, 405-408 [Medline] [Order article via Infotrieve]
  62. Renkawitz, R. (1990) Trends Genet. 6, 192-197 [CrossRef][Medline] [Order article via Infotrieve]
  63. Herschbach, B. M., and Johnson, A. D. (1993) Annu. Rev. Cell Biol. 9, 479-509 [CrossRef]
  64. Gill, G., and Ptashne, M. (1988) Nature 334, 721-724 [CrossRef][Medline] [Order article via Infotrieve]
  65. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. (1992) Science 255, 459-462 [Medline] [Order article via Infotrieve]
  66. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shek, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 12028-12032 [Abstract]
  67. Abdellatif, M., MacLellan, W. R., and Schneider, M. D. (1994) J. Biol. Chem. 269, 15423-15426 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.